routine surveillance MRI is better for insurance and patient
Posted: Sun Feb 02, 2014 12:57 am
If you were already Dx with the brain metastases that were treated by the radiosurgery or surgery and now you are denied to have a follow up MRI, this article may help you.
BACKGROUND:
Insurers have started to deny reimbursement for routine brain surveillance with magnetic resonance imaging (MRI) after stereotactic radiosurgery (SRS) for brain metastases in favor of symptom-prompted imaging. The authors investigated the clinical and economic impact of symptomatic versus asymptomatic metastases and related these findings to the use of routine brain surveillance.
They studied 442 patients after they had SRS for brain metastases.
Routinely preforming surveillance MRI to detect asymptomatic brain metastases has clinical benefits and reduces the cost of care.
http://www.ncbi.nlm.nih.gov/pubmed/24452675
CONCLUSIONS:
Patients who presented with symptomatic brain metastases had worse clinical outcomes and cost more to manage than asymptomatic patients. The current findings argue that routine brain surveillance after radiosurgery has clinical benefits and reduces the cost of care. Cancer 2014;120:433-441. © 2013 American Cancer Society.
BACKGROUND:
Insurers have started to deny reimbursement for routine brain surveillance with magnetic resonance imaging (MRI) after stereotactic radiosurgery (SRS) for brain metastases in favor of symptom-prompted imaging. The authors investigated the clinical and economic impact of symptomatic versus asymptomatic metastases and related these findings to the use of routine brain surveillance.
They studied 442 patients after they had SRS for brain metastases.
Routinely preforming surveillance MRI to detect asymptomatic brain metastases has clinical benefits and reduces the cost of care.
http://www.ncbi.nlm.nih.gov/pubmed/24452675
CONCLUSIONS:
Patients who presented with symptomatic brain metastases had worse clinical outcomes and cost more to manage than asymptomatic patients. The current findings argue that routine brain surveillance after radiosurgery has clinical benefits and reduces the cost of care. Cancer 2014;120:433-441. © 2013 American Cancer Society.